Marksans Pharma (MARKSANS) Q4 25/26 earnings summary

Executive summary

• Achieved record FY26 revenue of ₹29,509.38 million, net profit attributable to owners of ₹4,179.00 million, and highest-ever profitability, driven by geographical diversification, portfolio expansion, and strong cash generation.

• Expanded international footprint with new subsidiaries in Germany, Canada, Ireland, and strengthened presence in Australia via branded prescription generics.

• North America remained the largest and fastest-growing market, with significant new product launches and a robust pipeline.

• Maintained robust cash balance of ₹6,341.37 million and net cash positive position.

• Board recommended a final dividend of ₹0.90 per share for FY26.

Financial highlights

• FY26 operating revenue reached ₹29,509.38 million, up 12.5% YoY; Q4 revenue was strong, with gross profit for FY26 at ₹16,740 million and gross margin at 56.7%.

• EBITDA for FY26 was ₹6,010 million (24.4% margin); Q4 EBITDA was ₹1,950 million (22.8% margin), up 54% YoY.

• FY26 profit after tax was ₹4,200 million; Q4 PAT was ₹1,490 million, up 64.3% YoY.

• EPS for FY26 was ₹9.22; Q4 EPS was ₹3.3.

• Net cash generated from operating activities was ₹4,581.25 million in FY26.

Outlook and guidance

• Targeting ₹40,000 million revenue by FY28, with a roadmap to double revenue in 3–5 years.

• FY27 revenue growth expected in the 15–20% range; EBITDA margins guided to remain at 20–21% despite raw material inflation.

• Focus on expanding OTC business, innovation, and new launches in key markets; plans to double Indian manufacturing capacity to 16bn units p.a.

• Over 200 product filings planned in the UK over the next four years; robust pipeline for North America and Europe.

• Strategic vision to become a top global consumer healthcare company by FY30.